Search

Author/Creator Fujiwara, Hisataka

1. Long‐term safety and efficacy of the sodium–glucose cotransporter 2 inhibitor, tofogliflozin, added on glucagon‐like peptide‐1 receptor agonist in Japanese patients with type 2 diabetes mellitus: A 52‐week open‐label, multicenter, post‐marketing clinical study. Issue 6 (28th May 2019)

Authors:
Terauchi, Yasuo; Fujiwara, Hisataka; Kurihara, Yuji; Suganami, Hideki; Tamura, Masahiro; Senda, Masayuki; Gunji, Ryoji; Kaku, Kohei
Journal:
Journal of diabetes investigation
Issue:
Volume 10:Issue 6(2019)
Page Start:
1518
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

3. Safety and effectiveness of tofogliflozin in elderly Japanese patients with type 2 diabetes mellitus: A post‐marketing study (J‐STEP/EL Study). Issue 6 (6th March 2017)

Authors:
Utsunomiya, Kazunori; Shimmoto, Naoki; Senda, Masayuki; Kurihara, Yuji; Gunji, Ryoji; Fujii, Shoko; Kakiuchi, Seigo; Fujiwara, Hisataka; Kameda, Hiroyuki; Tamura, Masahiro; Kaku, Kohei
Journal:
Journal of diabetes investigation
Issue:
Volume 8:Issue 6(2017)
Page Start:
766
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

4. Safety and efficacy of tofogliflozin in Japanese patients with type 2 diabetes mellitus in real‐world clinical practice: Results of 3‐month interim analysis of a long‐term post‐marketing surveillance study (J‐STEP/LT). Issue 5 (6th March 2019)

Authors:
Utsunomiya, Kazunori; Senda, Masayuki; Kakiuchi, Seigo; Kameda, Hiroyuki; Tamura, Masahiro; Kurihara, Yuji; Gunji, Ryoji; Fujii, Shoko; Fujiwara, Hisataka; Kaku, Kohei
Journal:
Journal of diabetes investigation
Issue:
Volume 10:Issue 5(2019)
Page Start:
1272
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗